Targeted gene knockout in mammalian cells by using engineered zinc-finger nucleases

  1. Yolanda Santiago*,
  2. Edmond Chan*,
  3. Pei-Qi Liu*,
  4. Salvatore Orlando*,
  5. Lin Zhang,
  6. Fyodor D. Urnov*,
  7. Michael C. Holmes*,
  8. Dmitry Guschin*,
  9. Adam Waite*,
  10. Jeffrey C. Miller*,
  11. Edward J. Rebar*,
  12. Philip D. Gregory*,,
  13. Aaron Klug,§, and
  14. Trevor N. Collingwood*
  1. *Sangamo BioSciences, Inc., 501 Canal Boulevard, Suite A100, Richmond, CA 94804;
  2. Pfizer, Inc., Bioprocess Research and Development, Cell Line Development, 700 Chesterfield Parkway West, Chesterfield, MO 63017; and
  3. §Medical Research Council Laboratory of Molecular Biology, Hills Road, Cambridge CB2 2QH, United Kingdom
  1. Contributed by Aaron Klug, January 30, 2008 (received for review November 14, 2007)

Abstract

Gene knockout is the most powerful tool for determining gene function or permanently modifying the phenotypic characteristics of a cell. Existing methods for gene disruption are limited by their efficiency, time to completion, and/or the potential for confounding off-target effects. Here, we demonstrate a rapid single-step approach to targeted gene knockout in mammalian cells, using engineered zinc-finger nucleases (ZFNs). ZFNs can be designed to target a chosen locus with high specificity. Upon transient expression of these nucleases the target gene is first cleaved by the ZFNs and then repaired by a natural—but imperfect—DNA repair process, nonhomologous end joining. This often results in the generation of mutant (null) alleles. As proof of concept for this approach we designed ZFNs to target the dihydrofolate reductase (DHFR) gene in a Chinese hamster ovary (CHO) cell line. We observed biallelic gene disruption at frequencies >1%, thus obviating the need for selection markers. Three new genetically distinct DHFR −/− cell lines were generated. Each new line exhibited growth and functional properties consistent with the specific knockout of the DHFR gene. Importantly, target gene disruption is complete within 2–3 days of transient ZFN delivery, thus enabling the isolation of the resultant DHFR −/− cell lines within 1 month. These data demonstrate further the utility of ZFNs for rapid mammalian cell line engineering and establish a new method for gene knockout with application to reverse genetics, functional genomics, drug discovery, and therapeutic recombinant protein production.

Footnotes

  • To whom correspondence may be addressed. E-mail: pgregory{at}sangamo.com or akl{at}mrc-lmb.cam.ac.uk
  • Author contributions: P.-Q.L., F.D.U., M.C.H., D.G., J.C.M., E.J.R., P.D.G., and T.N.C. designed research; Y.S., E.C., P.-Q.L., S.O., A.W., and J.C.M. performed research; P.-Q.L., L.Z., E.J.R., P.D.G., and T.N.C. analyzed data; and P.D.G., A.K., and T.N.C. wrote the paper.

  • Conflict of interest statement: Y.S., E.C., P.-Q.L., S.O., F.D.U., M.C.H, D.G., J.C.M., E.J.R., P.D.G., and T.N.C. are full-time employees of Sangamo BioSciences, Inc. A.K. is a member of the scientific advisory board for Sangamo BioSciences, Inc. L.Z. is a full-time employee of Pfizer, Inc.

  • See Commentary on page 5653.

  • This article contains supporting information online at www.pnas.org/cgi/content/full/0800940105/DCSupplemental.

  • Freely available online through the PNAS open access option.

« Previous | Next Article »Table of Contents
OPEN ACCESS ARTICLE
From the Cover